Репозиторій Вінницького національного медичного університету імені М. І. Пирогова

Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions

Показати скорочений опис матеріалу

dc.contributor.author Victor Naestholt Dahl
dc.contributor.author Ole Skouvig Pedersen
dc.contributor.author Butova, Tetiana
dc.contributor.author Kuzhko, Mykhailo
dc.contributor.author Raznatovska, Olena
dc.contributor.author Bogomolov, Artemii
dc.date.accessioned 2025-12-09T22:01:06Z
dc.date.available 2025-12-09T22:01:06Z
dc.date.issued 2025
dc.identifier.citation Dahl VN, Skouvig Pedersen O, Butova T, Kuzhko M, Raznatovska O, Fedorec A, Vekshyn V, Hlynenko V, Yevsiukova N, Hryshchuk L, Kornaha S, Chursina N, Kondratyuk N, Markovtsiy L, Skryp V, Bogomolov A, Klymenko T, Yankovska D, Ostrovskyy M, Makoida I, Levandovska D, Shpak Y, Didyk V, Siomak O, Butov D. Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions. Clin Infect Dis. 2025 Nov 6;81(4):853-856. doi: 10.1093/cid/ciaf214. PMID: 40280886; PMCID: PMC12596402. uk_UA
dc.identifier.issn 1058-4838
dc.identifier.uri https://dspace.vnmu.edu.ua/123456789/11037
dc.description.abstract Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% success rate (394 of 460) under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trial findings (80%-90%). However, access and implementation remain a concern in conflict-affected settings. uk_UA
dc.language.iso en uk_UA
dc.publisher Clinical Infectious Diseases uk_UA
dc.relation.ispartofseries 81(15);853–858
dc.subject bedaquiline; linezolid; moxifloxacin; pretomanid; tuberculosis uk_UA
dc.title Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions uk_UA
dc.type Article uk_UA


Файли цього елементу

Даний матеріал зустрічається у наступних зібраннях

Показати скорочений опис матеріалу

Пошук


Перегляд

Мій обліковий запис